Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been living with chronic pain for at least 6 months
- People whose pain rates at least 4 out of 10 on a pain scale
- People who experience pain every day, or almost every day
- People whose pain has been identified by a doctor as a nerve-related pain type (called neuropathic pain) or a pain type linked to how the nervous system processes pain (called nociplastic pain)
- People who have previously received a brain stimulation treatment called rTMS at the pain centre as part of their regular care, but where the benefit did not last — specifically, where pain improved by at least 30% but the improvement lasted less than one month
- People who are registered with French social security (confirm with trial site)
Who may not be able to join:
- People for whom the brain stimulation treatment used in this trial (tDCS) is not considered safe, such as those with an implanted medical device, severe memory or thinking problems, epilepsy, skin conditions in the area where electrodes would be placed, certain blood clot conditions, metal implants in the skull, prior skull surgery, a brain aneurysm, a brain tumour, or severe sleep conditions such as narcolepsy
- People taking medications that may increase the risk of seizures, such as high doses of opioid painkillers (equivalent to 140 mg or more of morphine per day) or high doses of tricyclic antidepressants (150 mg or more per day)
- People who are pregnant or breastfeeding
- People under 18 or over 80 years of age
- People who have an ongoing legal case related to their pain
- People whose pain has been assessed as more severe than nerve-related or nociplastic pain and requires a different type of treatment
- People with a serious illness such as cancer
- People with a severe psychiatric condition such as psychosis
- People who would not be able to attend follow-up appointments for up to 3 months
- People who have taken part in another clinical trial within the past 3 months
- People with a history of psychoactive drug misuse
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nadine ATTAL, MD PhD, Institut National de la Santé Et de la Recherche Médicale, France
Phone: 0033149095931
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Self reported pain intensity in a diary
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.